key: cord-0763485-khg6iz82
authors: Pezzani, Maria Diletta
title: COVID-19 Outbreak: the gold rush and the Responsibilities of the scientific community
date: 2020-05-15
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.05.002
sha: 9e771dfbc33031100997e60043018296e33664bc
doc_id: 763485
cord_uid: khg6iz82

nan

With 3.435.894 confirmed cases [1] , major efforts from national governments and scientific society aim to set 25 actions to contain and limit further spread, and to improve global knowledge on the disease pathogenesis 

At this point, an obvious question comes to mind: how much can we rely on this literature? Is it really the 34 product of an evidence based medicine? The first impression is that this pandemic has led to a sort of "gold 35 rush" where the gold is the publication at the expense of the quality of the paper contents. The final result of 36 this hectic publication rhythm is to increase uncertainties rather than decreasing them as, on a given day, 37 there is an "evidence" for a treatment which is likely to be contradicted the day after. . This is reasonably understandable 65

given the emergency of the current situation and the urgent need to share data which are published without 66 4 following the usual peer-review track. Ultimately, the role of the guidelines is to provide a summary of the 67 best available evidence to support and aware clinicians on the use of drugs for which the harm to benefit 68 ratio is doubtful. However, by keeping a similar trend, the questionable quality of the studies will jeopardize 69 the accuracy of future results and here we would go back to the original question (how can we trust this 70 literature?) and to the uncertainties where we come from. Paraphrasing Richard Feynman, if we allow to live 71 with answers that might be wrong, as we progress, we remain unsure and we will leave opportunities for 72 alternatives.

We need accurate evidence before exposing, unethically, patients to unproven therapies where benefits 74 might exceed potential harms. Evidence based medicine relies on a combination between well designed 

Organization WHO. Coronavirus disease 2019 (COVID-19). Situation Report -105

A Novel Coronavirus from Patients with 118 Pneumonia in China

The many estimates of the COVID-19 case 120 fatality rate

Absolute and Relative Case-Fatality Risks during Outbreaks. PLoS neglected tropical diseases

Case-Fatality Rate and Characteristics of Patients Dying in Relation to 125

COVID-19 in Italy

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with 129 COVID-19 2020

Pharmacologic Treatments for Coronavirus 131 Disease 2019 (COVID-19): A Review

Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical 133

Increasing value and 135 reducing waste in research design, conduct, and analysis

Finding Effective Treatments for COVID-19